SLNO Q3 2018 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$4M

Net Income

-$3M

EPS (Diluted)

$-1.91

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$211,000

Balance Sheet

Total Assets

$31M

Total Liabilities

$17M

Stockholders' Equity

$14M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$3M	+100.0%
Operating Income	-$4M	-$3M	-44.2%
Net Income	-$3M	-$4M	+27.7%